Using optical coherence tomographic angiography (OCT-angiography), we examined the vasculature of the choriocapillaris in patients with central serous chorioretinopathy (CSC).
The prospective observational clinical study included patients with CSC defined by painless loss of central visual acuity and presence of a serous macular detachment as visualized by spectral-domain OCT. All eyes underwent OCT-angiography. Subfoveal choroidal thickness and choriocapillaris width were measured.
The study included 26 eyes of 21 patients with a mean age of 47.0 ± 7.9 years (range: 34–65 years). All 26 eyes showed an image pattern of high signal intensity, and 21 eyes additionally demonstrated dilated capillaries in the OCT-angio images. The areas showing abnormalities in the OCT-angiography were congruent with leaking areas in fluorescein angiography or areas with hyperpermeability in indocyanine green angiography. Among 16 patients with unilateral CSC, 1 patient showed a high intensity pattern in the OCT-angiogram in the contralateral, clinically unaffected eye. Parallel to thicker choroidal thickness measurements in affected eyes as compared with contralateral unaffected eyes in unilateral CSC, OCT-angiography revealed significantly thicker choriocapillaris measurements in the affected eyes. Conventional fluorescein angiography did not demonstrate leakage in 14 of 18 eyes with clinically diagnosed CSC.
Optical coherence tomographic angiography showed an image pattern of high signal intensity in all eyes with CSC and dilated vessels in the choriocapillaris in most eyes with clinically diagnosed CSC. The results indicate that OCT-angiography may become a noninvasive valuable tool for the diagnosis of CSC in particular and for the diagnosis of macular disorders in general.
Optical coherence tomographic angiography showed an image pattern of high signal intensity in all eyes with central serous chorioretinopathy (CSC) examined in this study, and dilated choriocapillaris vessels in most eyes with clinically diagnosed CSC. The results indicate that optical coherence tomographic angiography may become a noninvasive valuable tool for CSC diagnosis.
*Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Ophthalmology and Visual Science Key Laboratory, Capital Medical University, Beijing, China; and
†Department of Ophthalmology, Medical Faculty Mannheim of the Ruprecht-Karls-University, Mannheim, Germany.
Reprint requests: Wen Bin Wei, MD, Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Ophthalmology and Visual Science Key Laboratory, Capital Medical University, 1 Dong Jiao Min Xiang, Dong Cheng District, Beijing 100730, China; e-mail: firstname.lastname@example.org
Supported by the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (code: ZYLX201307); the National Natural Science Foundation of China (No. 81272981); the Beijing Natural Science Foundation (No. 7151003); and the Advanced Health Care Professionals Development Project of Beijing Municipal Health Bureau (No. 2014-2-003).
J. B. Jonas is a consultant for Allergan Inc, Merck Sharp & Dohme Co, Alimera Co, Boehringer Ingelheim Co, and Sanofi Co; patent holder with Biocompatible UK Ltd. (Treatment of Eye Diseases Using Encapsulated Cells Encoding And Secreting Neuroprotective Factor and/or Anti-angiogenic Factor; patent number: 20120263794), and patent application with University of Heidelberg (Agents for Use in the Therapeutic or Prophylactic Treatment of Myopia or Hyperopia; Europäische Patentanmeldung 15 000 771.4). None of the remaining authors have any conflicting interests to disclose.